For Health Institutions
Better innovation decisions. Before the deal is on the table.
Hospitals, health systems, investors, and accelerators use C.H.I.E.F.S.™ to evaluate the commercial readiness of health innovations independently before committing resources, capital, or institutional credibility to a venture that isn’t ready.
Independent evaluation
No relationship with the innovator. No conflict. A clean read.
Structured, defensible output
A scored report across 50 criteria — not an opinion, a framework.
Delivered in 48 hours
Fast enough to fit deal timelines. Thorough enough to rely on.
16 years of experience
Biomedical commercialization — not generic startup advisory.
Built for the organizations that evaluate health innovations — not just build them.
C.H.I.E.F.S.™ serves every institution that needs a rigorous, independent read on commercial readiness.
Hospitals & Health Systems
Evaluating a technology for procurement? C.H.I.E.F.S. gives your team a structured commercial-readiness view before you commit resources to a pilot or purchasing process.
Health Investors & VCs
Run an independent C.H.I.E.F.S. evaluation before or during due diligence — a scored view across 50 criteria that your team didn't produce and the founder can't coach.
Accelerators & Incubators
Benchmark your cohort. Identify which ventures are commercially ready and which need structured support before they face the market — or your investors.
Government & Funding Bodies
Granting bodies and public health funders use C.H.I.E.F.S. to assess whether funded ventures have the commercial infrastructure to convert public investment into real-world adoption.
Evaluating health innovations is harder than it looks.
Institutions encounter hundreds of innovations a year — through inbound pitches, accelerator partnerships, procurement processes, and investment pipelines. Most of them look similar at the surface. The gaps aren't visible until someone looks for them.
C.H.I.E.F.S. gives institutions the language, the structure, and the scored output to make those decisions faster, more consistently, and more defensibly.
Inconsistent internal evaluation
Different reviewers weigh different things. Without a shared framework, institutional decisions rely on whoever is in the room.
Founder-framed information
Every pitch deck is built to persuade. Institutions rarely have access to an evaluation that wasn't designed to impress — until due diligence, when it's often too late.
Commercial readiness ≠ clinical proof
Strong clinical evidence doesn't automatically translate to procurement readiness, payer acceptance, or scalable adoption.
Time and bandwidth constraints
Institutional teams rarely have capacity for deep commercial diligence on every venture they review. C.H.I.E.F.S. delivers a comprehensive read in 48 hours.
Four ways C.H.I.E.F.S.™ fits into your process.
From single-venture evaluation to portfolio-wide benchmarking.
Independent Diligence Support
Commission a C.H.I.E.F.S. evaluation on any venture in your pipeline — before, during, or alongside your internal due diligence process.
- Scored report across all 6 pillars and 50 criteria
- Delivered within 48 hours of the evaluation session
- No relationship with the innovator — genuinely independent
- Boardroom-ready format your investment committee can rely on
Cohort & Portfolio Benchmarking
Evaluate your entire accelerator cohort or investment portfolio through a single consistent framework — so you're comparing apples to apples.
- Consistent scoring methodology across every venture
- Identify which ventures need commercial development support
- Aggregate cohort view for reporting to funders and boards
- Prioritize resources toward ventures with highest commercial upside
Procurement Readiness Assessment
For hospitals and health systems evaluating a specific technology — C.H.I.E.F.S. gives your procurement team a structured view of commercial and operational readiness.
- Health-Economics pillar directly addresses payer and cost arguments
- Execution pillar surfaces operational and delivery risks early
- Scalability pillar flags whether the vendor can support a system rollout
- Report format supports internal approval and governance processes
Advisory & Ongoing Engagement
For institutions that want more than a one-time report — ongoing advisory to support commercialization strategy across a portfolio or program.
- Structured commercialization roadmaps for ventures in your portfolio
- Periodic re-evaluation as ventures progress through milestones
- Workshop delivery for institutional teams on commercialization frameworks
- Direct access to Dan Wasserman for strategic consultation
Three ways to work with Mammoth.
Single evaluation, portfolio program, or ongoing advisory — structured to fit how your institution actually operates.
Single Evaluation
One venture. One report. Delivered in 48 hours.
Full C.H.I.E.F.S. evaluation across 6 pillars and 50 criteria
Live Zoom session with Dan Wasserman
Written Findings Report with aggregate score and ranked actions
No NDA — works entirely from public-domain materials
Cohort / Portfolio Program
Multiple ventures. Consistent framework. Comparable outputs.
Evaluation of 3–20+ ventures using the same C.H.I.E.F.S. methodology
Portfolio summary view for board and funder reporting
Individual Findings Reports delivered to each venture
Coordinated scheduling across your cohort calendar
Ongoing Advisory
Sustained engagement across programs and timelines.
Periodic re-evaluation as ventures advance through milestones
Commercialization strategy support for ventures in your portfolio
Workshop delivery for institutional teams
Direct access to Dan Wasserman for ongoing strategic consultation
How an institutional engagement runs.
From first conversation to a defensible commercial read on any venture in your pipeline.
Institutional briefing call — 30 minutes
We discuss your pipeline, your evaluation needs, and the format that fits your process — whether that's a single venture, a full cohort, or an ongoing advisory arrangement. No commitment required.
You identify the venture(s) to be evaluated
The innovator is notified and submits their public-domain materials directly. No NDA is required. Your institution doesn't handle the intake — we do. The process is clean and founder-neutral.
C.H.I.E.F.S. evaluation is conducted
Dan Wasserman conducts the evaluation live on Zoom with the innovator's team. The session runs approximately 90 minutes — structured, scored, and thorough. Your institution is not present unless specifically requested.
You receive the Findings Report within 48 hours
The written report is delivered to both the institution and the innovator simultaneously — aggregate score, factor-by-factor breakdown, and ranked recommendations in a format your board or procurement team can act on directly.
How C.H.I.E.F.S.™ compares to your current options.
Generic due diligence frameworks weren't built for health innovation. C.H.I.E.F.S. was.
| Capability | C.H.I.E.F.S.™ | Internal Review | Generic DD Firm | Pitch Review |
|---|---|---|---|---|
| Health-specific commercialization criteria | ✓ | ~ Varies | ✗ | ✗ |
| Scored output across 50 criteria | ✓ | ✗ | ~ Sometimes | ✗ |
| Independent of the innovator | ✓ | ~ Depends | ✓ | ✗ |
| Delivered in 48 hours | ✓ | ✗ | ✗ | ~ |
| No NDA or confidential materials required | ✓ | ✗ | ✗ | ✓ |
| Ranked action recommendations | ✓ | ~ Varies | ~ Sometimes | ~ |
| Cohort / portfolio benchmarking | ✓ | ✗ | ~ At cost | ✗ |
What institutions ask before they engage.
What institutional partners say.
We needed a consistent framework to evaluate our cohort before demo day. C.H.I.E.F.S. gave every venture the same honest read — and told us exactly which ones were ready for investor conversations and which ones weren't.
Our investment committee needed more than a pitch deck and a founder's word. The C.H.I.E.F.S. report gave us a scored, structured basis for the decision. It changed how we run early-stage health diligence.
Request an institutional briefing →
We'll walk you through how C.H.I.E.F.S. fits your pipeline.
A 30-minute call with Dan Wasserman. Direct, candid, and useful — whether you engage formally or not.